CompletedNCT00866996
Extended-release methylphenidate or atomoxetine for children with ADHD
About this title
Read the official source — NCT00866996Medication studyAges 6–12
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,323
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Not clearly listed
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00866996
- Official title
Show the full official title
A Multi-center Randomized Parallel Group Study Evaluating Treatment Outcomes of Concerta (Extended Release Methylphenidate) and Strattera (Atomoxetine) in Children With Attention-deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate extended-release; Atomoxetine.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
